Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Septic Shock Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 28 Oct 16

Research and Markets has announced the addition of the "Septic Shock - Pipeline Review, H2 2016" report to their offering.

Septic Shock Septic shock is a serious condition that occurs when an overwhelming infection leads to life-threatening low blood pressure. Septic shock occurs most often in the very old and the very young. Any type of bacteria can cause septic shock. Fungi and (rarely) viruses may also cause the condition. Toxins released by the bacteria or fungi may cause tissue damage, and may lead to low blood pressure and poor organ function. Symptoms include patches of discolored skin, confusion, chills due to fall in body temperature, extreme weakness or lightheadedness.

Septic Shock pipeline therapeutics constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by Companies and remaining by the Universities Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 2, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Septic Shock - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Septic Shock Overview
  3. Therapeutics Development
  4. Pipeline Products for Septic Shock - Overview
  5. Pipeline Products for Septic Shock - Comparative Analysis
  6. Septic Shock - Therapeutics under Development by Companies
  7. Septic Shock - Therapeutics under Investigation by Universities/Institutes
  8. Septic Shock Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Septic Shock - Products under Development by Companies
  13. Septic Shock - Products under Investigation by Universities/Institutes
  14. Septic Shock - Companies Involved in Therapeutics Development
  • Adrenomed AG
  • Ferring International Center S.A.
  • Huons Co., Ltd.
  • InflaRx GmbH
  • Inotrem S.A.
  • Lixte Biotechnology Holdings, Inc.
  • Noxxon Pharma AG
  • Octapharma AG
  • Orion Oyj
  • Peptinov SAS
  • Pharmazz, Inc.
  • Spider Biotech
  • Takeda Pharmaceutical Company Limited
  • Therashock, LLC
  • ViiV Healthcare Limited
  • XImmune AB

For more information about this report visit http://www.researchandmarkets.com/research/fc2dhz/septic_shock

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005370/en/

Business Wire
www.businesswire.com

Last updated on: 28/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.